MCID: DBT008
MIFTS: 48

Diabetic Angiopathy

Categories: Cardiovascular diseases

Aliases & Classifications for Diabetic Angiopathy

MalaCards integrated aliases for Diabetic Angiopathy:

Name: Diabetic Angiopathy 12 72 14
Diabetic Angiopathies 51 41 69
Diabetic Vascular Disorder 12

Classifications:



External Ids:

Disease Ontology 12 DOID:11713
MeSH 41 D003925
NCIt 46 C35610
UMLS 69 C0011875

Summaries for Diabetic Angiopathy

MalaCards based summary : Diabetic Angiopathy, also known as diabetic angiopathies, is related to vasculitis and vascular disease. An important gene associated with Diabetic Angiopathy is IGFBP7 (Insulin Like Growth Factor Binding Protein 7), and among its related pathways/superpathways are Glucose / Energy Metabolism and Longevity regulating pathway. The drugs Bevacizumab and Ranibizumab have been mentioned in the context of this disorder. Affiliated tissues include eye, skin and bone, and related phenotypes are cellular and cardiovascular system

Wikipedia : 72 Diabetic angiopathy is a form of angiopathy associated with diabetic complications. While not exclusive,... more...

Related Diseases for Diabetic Angiopathy

Diseases related to Diabetic Angiopathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 67)
# Related Disease Score Top Affiliating Genes
1 vasculitis 28.8 CCL2 SELE THBD VWF
2 vascular disease 25.9 AGER CAT CCL2 EDN1 INS MTHFR
3 intracranial thrombosis 10.3 MTHFR VWF
4 retinal vascular occlusion 10.3 CCL2 MTHFR
5 osteoporotic fracture 10.3 MTHFR TNFRSF11B
6 unilateral absence of a pulmonary artery 10.3 THBD VWF
7 ischemic heart disease 10.3 CCL2 MTHFR
8 type 1 diabetes mellitus 10 10.2 CAT SOD2
9 diabetic polyneuropathy 10.2 AGER SOD2
10 marantic endocarditis 10.2 MTHFR THBD
11 microvascular complications of diabetes 3 10.1 AGER INS
12 mesangial proliferative glomerulonephritis 10.1 CCL2 EDN1
13 pediatric osteosarcoma 10.1 EDN1 MTHFR
14 spotted fever 10.1 THBD VWF
15 myocardial stunning 10.1 CAT EDN1
16 scleritis 10.0 CCL2 SELE
17 uremia 10.0 INS TNFRSF11B VWF
18 blood coagulation disease 10.0 MTHFR THBD VWF
19 thrombophilia due to activated protein c resistance 10.0 MTHFR THBD VWF
20 thrombophilia due to thrombin defect 10.0 MTHFR THBD VWF
21 thrombosis 10.0 MTHFR THBD VWF
22 lutheran suppressor, x-linked 10.0 EDN1 INS
23 neuropathy 10.0
24 thrombophilia 10.0 MTHFR THBD VWF
25 idiopathic edema 9.9 EDN1 INS
26 stroke, ischemic 9.9 MTHFR THBD VWF
27 buerger disease 9.9 MTHFR SELE
28 aspirin resistance 9.9
29 endotheliitis 9.9
30 hepatic vascular disease 9.9 EDN1 MTHFR
31 boutonneuse fever 9.9 SELE THBD
32 eisenmenger syndrome 9.8 EDN1 THBD VWF
33 raynaud disease 9.8 EDN1 THBD VWF
34 chronic active epstein-barr virus infection 9.8 SELE THBD
35 collagen disease 9.8 EDN1 THBD VWF
36 tetralogy of fallot 9.8 CAT EDN1 MTHFR
37 fascioliasis 9.8 INS SELE
38 urinary system disease 9.8 CCL2 EDN1 INS
39 renovascular hypertension 9.8 CAT EDN1
40 shwartzman phenomenon 9.7 SELE THBD
41 eclampsia 9.7 EDN1 MTHFR THBD
42 coronary artery anomaly 9.7 EDN1 INS MTHFR
43 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 9.7
44 diabetes mellitus 9.7
45 hyperglycemia 9.7
46 pancreatitis 9.7
47 thyroiditis 9.7
48 legg-calve-perthes disease 9.7 SELE THBD
49 thrombotic thrombocytopenic purpura 9.7 SELE THBD VWF
50 takayasu arteritis 9.7 SELE THBD VWF

Graphical network of the top 20 diseases related to Diabetic Angiopathy:



Diseases related to Diabetic Angiopathy

Symptoms & Phenotypes for Diabetic Angiopathy

MGI Mouse Phenotypes related to Diabetic Angiopathy:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.02 CAT SOD2 THBD IGFBP7 INS TNFRSF11B
2 cardiovascular system MP:0005385 10.01 SOD2 EDN1 THBD INS TNFRSF11B VWF
3 growth/size/body region MP:0005378 9.97 SELE AGER SOD2 EDN1 IGFBP7 THBD
4 homeostasis/metabolism MP:0005376 9.91 SELE AGER CAT SOD2 EDN1 THBD
5 immune system MP:0005387 9.76 SELE AGER CCL2 SOD2 THBD INS
6 integument MP:0010771 9.5 AGER SOD2 IGFBP7 THBD INS MTHFR
7 mortality/aging MP:0010768 9.28 SELE CAT SOD2 EDN1 THBD INS

Drugs & Therapeutics for Diabetic Angiopathy

Drugs for Diabetic Angiopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 451)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 216974-75-3
2
Ranibizumab Approved Phase 4,Phase 3,Phase 2,Phase 1 347396-82-1 459903
3
Amoxicillin Approved, Vet_approved Phase 4,Phase 3 26787-78-0 33613 2171
4
Aztreonam Approved Phase 4,Phase 2 78110-38-0 5742832 5362041
5
Clindamycin Approved, Vet_approved Phase 4,Phase 2 18323-44-9 29029
6
Levofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2 100986-85-4 149096
7
Linezolid Approved, Investigational Phase 4,Phase 2 165800-03-3 441401
8
Metronidazole Approved Phase 4,Phase 2 443-48-1 4173
9
Ofloxacin Approved Phase 4,Phase 3,Phase 2 82419-36-1 4583
10
Piperacillin Approved Phase 4,Phase 3,Phase 2 66258-76-2 43672
11
Tazobactam Approved Phase 4,Phase 3,Phase 2 89786-04-9 123630
12
Fenofibrate Approved Phase 4,Phase 3 49562-28-9 3339
13
Hydroxocobalamin Approved Phase 4 13422-51-0 5460373 44475014 11953898
14
Glatiramer Acetate Approved, Investigational Phase 4 147245-92-9 3081884
15
Mannitol Approved, Investigational Phase 4 69-65-8 6251 453
16
Acarbose Approved, Investigational Phase 4,Early Phase 1 56180-94-0 441184
17
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
18
Ciprofloxacin Approved, Investigational Phase 4,Phase 2,Phase 1 85721-33-1 2764
19
Sulfamethoxazole Approved Phase 4,Phase 2 723-46-6 5329
20
Trimethoprim Approved, Vet_approved Phase 4,Phase 2 738-70-5 5578
21
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1 7440-66-6 32051 23994
22
Alginic acid Approved, Experimental, Investigational Phase 4,Phase 1,Phase 2 9005-32-7
23
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 2713 9552079
24
Latanoprost Approved, Investigational Phase 4 130209-82-4 5311221 5282380
25
Petrolatum Approved, Investigational Phase 4 8009-03-8
26
Dipivefrin Approved Phase 4 52365-63-6 3105
27
Cefepime Approved, Investigational Phase 4,Phase 2 88040-23-7 5479537
28
Cefotaxime Approved Phase 4 63527-52-6 5742673 456256
29
Cefoxitin Approved Phase 4 35607-66-0 441199
30
Ceftriaxone Approved Phase 4 73384-59-5 5479530 5361919
31
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 564-25-0 54671203
32
Fusidic Acid Approved, Investigational Phase 4 6990-06-3 3000226
33
Rifampin Approved Phase 4 13292-46-1 5381226 5458213
34
Insulin Glargine Approved Phase 4,Early Phase 1 160337-95-1
35
Ampicillin Approved, Vet_approved Phase 4 69-53-4 6249
36
Sulbactam Approved Phase 4 68373-14-8
37 Sultamicillin Approved, Investigational Phase 4 76497-13-7
38
Temazepam Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 846-50-4 5391
39
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-78-2 2244
40
Vancomycin Approved Phase 4,Phase 3,Phase 2 1404-90-6 14969 441141
41
Allopurinol Approved Phase 4 315-30-0 2094
42
Saxagliptin Approved Phase 4 361442-04-8 11243969
43
Empagliflozin Approved Phase 4 864070-44-0
44
Glimepiride Approved Phase 4 93479-97-1 3476
45
Daptomycin Approved, Investigational Phase 4,Phase 3,Phase 2 103060-53-3 16129629
46
Dimenhydrinate Approved Phase 4 523-87-5 441281
47
Bacitracin Approved, Vet_approved Phase 4 1405-87-4 10909430 439542
48
Thrombin Approved, Investigational Phase 4
49
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
50
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-30-3 6037

Interventional clinical trials:

(show top 50) (show all 836)

# Name Status NCT ID Phase Drugs
1 Laser Therapy Combined With Intravitreal Aflibercept vs Intravitreal Aflibercept Monotherapy (LADAMO) Unknown status NCT02432547 Phase 4 Aflibercept
2 A Comparative Efficacy Study of DermaPure™ to Treat Diabetic Foot Ulcers Unknown status NCT02081352 Phase 4
3 PASCAL Laser Versus ETDRS Laser Associated With Intravitreal Ranibizumab (IVR) Versus Only IVR for Proliferative Diabetic Retinopathy Unknown status NCT02005432 Phase 4 Intravitreal Ranibizumabe;panfotocoagulation (PASCAL);panfotocoagulation (PRP) single shoot (ETDRS)
4 Efficacy and Safety of Garamycin® Sponge (Gentamicin-Collagen Sponge) in Diabetic Patients With a Moderate or Severe Foot Ulcer Infection Unknown status NCT01951768 Phase 4 Garamycin Sponge (Gentamicin-Collagen sponge);Systemic Antibiotic
5 Effects of Fenofibrate on Endothelial Progenitor Cells in Diabetes Unknown status NCT01927315 Phase 4 Fenofibrate 145 mg;Placebo
6 Effect of Folic Acid, Vitamin B6 and Vitamin B12 in Diabetic Retinopathy Unknown status NCT01921192 Phase 4 Folic Acid, vit B6 and B12;Placebo
7 Macugen for Proliferative Diabetic Retinopathy Study With Extended Dosing (M-PDRS ED) Unknown status NCT01486771 Phase 4 Macugen ® (pegaptanib sodium)
8 Effect of Doxium on High Sensitivity CRP and Endothelin-1 Serum Levels in Patients With Diabetic Retinopathy Unknown status NCT01382498 Phase 4 Calcium dobesilate (Doxium);Placebo drug
9 Clinical Evaluation of the SNaP Wound Care System Unknown status NCT01113658 Phase 4
10 Panretinal Photocoagulation for Proliferative Diabetic Retinopathy in a Single Session Using Low Fluence Parameters Unknown status NCT01023698 Phase 4
11 Use of Intravitreal Ranibizumab in the Treatment of Vitreous Hemorrhage Unknown status NCT01824043 Phase 4 intravitreal ranibizumab injections
12 Effects of Copaxone in the Retinal Function in Diabetic Patients After Panphotocoagulation Unknown status NCT00677664 Phase 4 Glatiramer acetate (Copaxone);Mannitol
13 Changes in Macular Thickness After Patterns Scan Laser Unknown status NCT00563628 Phase 4
14 Changes in Electroretinogram and Contrast Sensitivity After PASCAL Treatment Unknown status NCT00563043 Phase 4
15 Ranibizumab in Diabetic Vitrectomy Unknown status NCT01306981 Phase 4 Ranibizumab;Saline
16 Thiazolidinedione (TZD) on the Diabetic Retinopathy and Nephropathy Unknown status NCT01175486 Phase 4 Actos (Pioglitazone);Acarbose
17 Bevacizumab and Peripheral Retinal Changes on Wide Field Angiography in Diabetic Macular Edema Unknown status NCT02096874 Phase 4 Bevacizumab
18 Pegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease(Preserve) Study Completed NCT01486238 Phase 4 Macugen® pegaptanib sodium
19 Diabetic Foot Ulcer Study on Topical Interventions Completed NCT02577900 Phase 4
20 GrafixCORE®: Open-Label Study to Evaluate the Safety and Efficacy of GrafixCORE® for Complex Diabetic Foot Wounds Completed NCT02260609 Phase 4
21 Diabetic Foot Ulcer. Effectiveness of Chlorhexidine Gluconate 0.125 % Compared With Sterile Deionized Water Completed NCT02097615 Phase 4
22 DermACELL in Subjects With Chronic Wounds of the Lower Extremities Completed NCT01970163 Phase 4
23 GrafixPRIME® for the Treatment of Chronic Diabetic Foot Ulcers Completed NCT02675855 Phase 4
24 Use of Santyl in Diabetic Foot Ulcers Completed NCT02581488 Phase 4
25 Santyl vs. Sharp Debridement of Diabetic Foot Wounds Completed NCT01056198 Phase 4 Santyl
26 Santyl Applications to Diabetic Foot Ulcers Completed NCT02111291 Phase 4
27 TITLE: An Open, Non-comparative, Multi-centre Post Marketing Clinical Follow-up (PMCF) Investigation to Evaluate Performance and Safety on Diabetic Foot Ulcer, DFU, When Using Mepilex Transfer Ag as Intended Completed NCT01964521 Phase 4
28 Study of Oasis Ultra in Diabetic Foot Ulcers Completed NCT01835379 Phase 4
29 A Complicated Skin and Soft-tissue Infection Patient Registry Completed NCT00737269 Phase 4
30 Grafix® DFU: Open-Label Extension Option to Evaluate Safety & Efficacy of Grafix® for Chronic Diabetic Foot Ulcers Completed NCT01596920 Phase 4
31 Multicenter 12 Months Clinical Study to Evaluate Efficacy and Safety of Ranibizumab Alone or in Combination With Laser Photocoagulation vs. Laser Photocoagulation Alone in Proliferative Diabetic Retinopathy (PRIDE) Completed NCT01594281 Phase 4 Ranibizumab
32 LeucoPatch™ Study A Multicenter Study on the Effect of LeucoPatch™ in Diabetic Foot Ulcers Completed NCT01454401 Phase 4
33 Using Santyl on Diabetic Foot Ulcers Completed NCT01408277 Phase 4
34 Study of Efficacy of Ranibizumab in Different Regimens in Patients With Diabetic Macula Edema Completed NCT02366468 Phase 4 0.5 mg ranibizumab;0.5 mg ranibizumab
35 Topical Application of Latanoprost in Diabetic Retinopathy Completed NCT01225653 Phase 4 Latanoprost
36 Wound Edge Changes Following Treatment With Santyl Completed NCT01197898 Phase 4
37 PRELIMINARY EVALUATION OF PHARMACOLOGICAL LOWERING OF AGEs Completed NCT02249897 Phase 4 CHOLESTYRAMINE
38 Enzymatic Versus (vs) Autolytic Debridement of Diabetic Foot Ulcers Completed NCT01143727 Phase 4 Santyl;Tegaderm Hydrogel
39 A Study to Look at the Effects of Four Weeks of Treatment on the Healing of Diabetic Foot Ulcers Completed NCT01143714 Phase 4 Santyl
40 Trial of Vacuum Assisted Closure® Therapy in Amputation Wounds of the Diabetic Foot Completed NCT00224796 Phase 4
41 Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy Completed NCT01025934 Phase 4 Bevacizumab
42 Prospective Randomized Controlled Study of Intravitreal Injection of Bevacizumab for Proliferative Diabetic Retinopathy Completed NCT01854593 Phase 4 Bevacizumab
43 Pain Using Reduced Fluence Parameters in Photocoagulation for Diabetic Retinopathy. Completed NCT00802269 Phase 4
44 Evaluation of the Effect of Vivostat Platelet Rich Fibrin(PRF) in the Treatment of Diabetic Foot Ulcers Completed NCT00770939 Phase 4
45 Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy Completed NCT01724385 Phase 4 intravitreal injection of bevacizumab
46 Intravitreal Ranibizumab Injection as Adjuvant in the Treatment of Postvitrectomy Diabetic Vitreous Hemorrhage Accompanied by Neovascular Glaucoma Completed NCT02647515 Phase 4 ranibizumab
47 OASIS Wound Matrix (Oasis) Mechanism of Action Completed NCT00570141 Phase 4
48 Effect of the Adjunctive IVB Before PRP Completed NCT01504724 Phase 4 bevacizumab
49 Study Comparing VERSAJET With Conventional Surgical Procedures in the Removal of Unhealthy Tissue From Lower Limb Ulcers Completed NCT00521027 Phase 4
50 Antibiotic Treatment Duration for Non-Surgically-Treated Diabetic Foot Osteomyelitis Completed NCT02123628 Phase 4 duration of the antibiotic therapy

Search NIH Clinical Center for Diabetic Angiopathy

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: diabetic angiopathies

Genetic Tests for Diabetic Angiopathy

Anatomical Context for Diabetic Angiopathy

MalaCards organs/tissues related to Diabetic Angiopathy:

38
Eye, Skin, Bone, Bone Marrow, Endothelial, Testes, Retina

Publications for Diabetic Angiopathy

Articles related to Diabetic Angiopathy:

(show top 50) (show all 97)
# Title Authors Year
1
Redox Status of I^2GPI in Different Stages of Diabetic Angiopathy. ( 27818568 )
2016
2
[SMOKING AS A TRIGGER FACTOR IN THE DEVELOPMENT OF DIABETIC ANGIOPATHY OF LOWER EXTREMITIES IN MEN WITH METHYLENETETRAHYDROFOLATEREDUCTASE 677TT GENOTYPE]. ( 26596059 )
2015
3
Aspirin resistance, platelet turnover, and diabetic angiopathy: a 2011 update. ( 22142668 )
2012
4
Diabetic angiopathy and angiogenic defects. ( 22853690 )
2012
5
Is the advancement of diabetic angiopathy evaluated as ankle-brachial index directly associated with current glycaemic control? ( 23020057 )
2012
6
Diabetic angiopathy. ( 22616224 )
2011
7
Molecular pathology of oxidative stress in diabetic angiopathy: role of mitochondrial and cellular pathways. ( 20022399 )
2010
8
Macrophage foam cell formation is augmented in serum from patients with diabetic angiopathy. ( 19939487 )
2010
9
Diabetic angiopathy, the complement system and the tumor necrosis factor superfamily. ( 20098449 )
2010
10
Peroxynitrite-induced nitration of cyclooxygenase-2 and inducible nitric oxide synthase promotes their binding in diabetic angiopathy. ( 20607198 )
2010
11
Diabetes in motion in the year of the child. Meeting Highlights - 33rd Annual ISPAD Meeting, September 26-29, 2007, Berlin, Germany - 5th Symposium on Diabetic Angiopathy in Children, September 30, 2007, Berlin, Germany. ( 18211630 )
2008
12
Oxidative stress-responsive transcription factor ATF3 potentially mediates diabetic angiopathy. ( 16428460 )
2006
13
Effects of irbesartan on intracellular antioxidant enzyme expression and activity in adolescents and young adults with early diabetic angiopathy. ( 15983321 )
2005
14
Diabetic angiopathy: new experimental and clinical aspects. ( 15918103 )
2005
15
Impact of adiposity and plasma adipocytokines on diabetic angiopathies in Japanese Type 2 diabetic subjects. ( 15270792 )
2004
16
The role of nitric oxide in the development of diabetic angiopathy. ( 15156413 )
2004
17
Aspirin resistance and diabetic angiopathy: back to the future. ( 15115664 )
2004
18
Pathophysiological mechanisms of diabetic angiopathy. ( 12623164 )
2003
19
Monocyte adhesion in diabetic angiopathy: effects of free-radical scavenging. ( 12623165 )
2003
20
[Growth hormone, insulin-like growth factor and insulin-like growth factor binding protein in young type I diabetes patients with the onset of diabetic angiopathy]. ( 12868196 )
2003
21
Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. ( 12429856 )
2002
22
Advanced glycation end products, their receptors and diabetic angiopathy. ( 11694852 )
2001
23
The possible association of in vivo leukocyte-platelet heterophilic aggregate formation and the development of diabetic angiopathy. ( 11674859 )
2001
24
Growth hormone, IGF-I and diabetic angiopathy revisited. ( 10651747 )
2000
25
Long-term effects of the endothelin(A) receptor antagonist LU 135252 and the angiotensin-converting enzyme inhibitor trandolapril on diabetic angiopathy and nephropathy in a chronic type I diabetes mellitus rat model. ( 10773002 )
2000
26
Possible pathophysiological mechanisms for diabetic angiopathy in type 2 diabetes. ( 11004428 )
2000
27
Advanced glycation end products in adolescents and young adults with diabetic angiopathy. ( 10955941 )
2000
28
Circulating IGF-I and its protective role in the pathogenesis of diabetic angiopathy. ( 10651746 )
2000
29
Plasminogen activator inhibitor-1 and apolipoprotein E gene polymorphisms and diabetic angiopathy. ( 10809802 )
2000
30
[Pathophysiologic aspects of diabetic angiopathy]. ( 10421989 )
1999
31
Quality Control of Diabetes Care and Chronic Complications in Young People after St. Vincent and Kos. Proceedings of the 4th International Workshop Diabetic Angiopathy in Children. Berlin, Germany, September 4-6, 1997. ( 9742011 )
1998
32
Molecular mechanisms of diabetic angiopathy--clues for innovative therapeutic interventions. ( 9676989 )
1998
33
Urinary free cortisol and its nyctohemeral variation in adolescents and young adults with IDDM: relation to endothelin 1 and indices of diabetic angiopathy. ( 11517960 )
1998
34
Von Willebrand factor in diabetic angiopathy. ( 9805643 )
1998
35
Controversies on the pathogenesis of diabetic angiopathy: which treatment for normotensive adolescents with microalbuminuria and type 1 diabetes? ( 9642665 )
1998
36
Endothelial dysfunction and pathogenesis of diabetic angiopathy. ( 9217873 )
1997
37
Diabetic angiopathy in children. ( 9455928 )
1997
38
[Effects of xenotransplantation of pancreatic islet cells on immunological state of patients with diabetic angiopathies]. ( 9511343 )
1997
39
[The thromboxane-synthesis inhibitor Ibustrin in the treatment of diabetic angiopathies]. ( 9026936 )
1996
40
The role of hyperglycemia and hyperinsulinemia in the pathogenesis of diabetic angiopathy. ( 8905209 )
1996
41
Enhanced expression of platelet-derived growth factor-beta receptor by high glucose. Involvement of platelet-derived growth factor in diabetic angiopathy. ( 8603774 )
1996
42
Diabetic angiopathy: tracking down the culprits. ( 8807468 )
1996
43
[The medical effect of magnetic-laser therapy in patients with diabetic angiopathies of the lower extremities]. ( 9138797 )
1996
44
Prostacyclin-stimulating factor, novel protein, and diabetic angiopathy. ( 8674874 )
1996
45
Endothelial dysfunction and diabetic angiopathy. ( 7867890 )
1994
46
[The results of a comparative study of the lipid peroxidation processes and of the malondialdehyde level of the blood cells in patients with diabetic angiopathies and during insulin therapy]. ( 7863440 )
1994
47
[Activity of membrane-bound protein kinase C and ATPase in erythrocytes in diabetic angiopathy]. ( 8058653 )
1993
48
Cell-cell interactions in diabetic angiopathy. ( 1396014 )
1992
49
Effect of propionyl-L-carnitine in the treatment of diabetic angiopathy: controlled double blind trial versus placebo. ( 1644013 )
1992
50
[Acupuncture in the treatment of diabetic angiopathy of the lower extremities]. ( 1788185 )
1991

Variations for Diabetic Angiopathy

Expression for Diabetic Angiopathy

Search GEO for disease gene expression data for Diabetic Angiopathy.

Pathways for Diabetic Angiopathy

GO Terms for Diabetic Angiopathy

Cellular components related to Diabetic Angiopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.76 AGER CAT CCL2 EDN1 IGFBP7 INS
2 extracellular space GO:0005615 9.23 CAT CCL2 EDN1 IGFBP7 INS SELE
3 Weibel-Palade body GO:0033093 8.96 EDN1 VWF

Biological processes related to Diabetic Angiopathy according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 regulation of receptor activity GO:0010469 9.84 CCL2 EDN1 INS TNFRSF11B
2 inflammatory response GO:0006954 9.8 AGER CCL2 SELE TNFRSF11B
3 positive regulation of cell migration GO:0030335 9.76 EDN1 INS SOD2
4 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.7 AGER CAT INS
5 regulation of synaptic plasticity GO:0048167 9.6 AGER INS
6 response to amino acid GO:0043200 9.59 EDN1 MTHFR
7 response to interleukin-1 GO:0070555 9.58 MTHFR SELE
8 response to cadmium ion GO:0046686 9.57 CAT SOD2
9 positive regulation of mitotic nuclear division GO:0045840 9.56 EDN1 INS
10 glucose transport GO:0015758 9.55 EDN1 INS
11 response to drug GO:0042493 9.55 CAT EDN1 MTHFR SOD2 TNFRSF11B
12 response to hyperoxia GO:0055093 9.51 CAT SOD2
13 positive regulation of nitric oxide biosynthetic process GO:0045429 9.5 EDN1 INS SOD2
14 superoxide anion generation GO:0042554 9.48 EDN1 SOD2
15 negative regulation of blood coagulation GO:0030195 9.46 EDN1 THBD
16 negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway GO:1902176 9.43 INS SOD2
17 response to activity GO:0014823 9.43 CAT EDN1 SOD2
18 response to L-ascorbic acid GO:0033591 9.4 CAT SOD2
19 response to ozone GO:0010193 9.37 CAT EDN1
20 response to lipopolysaccharide GO:0032496 9.35 EDN1 SELE SOD2 THBD TNFRSF11B
21 response to hypoxia GO:0001666 9.02 AGER CAT EDN1 MTHFR SOD2

Molecular functions related to Diabetic Angiopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.13 CCL2 EDN1 TNFRSF11B
2 NADP binding GO:0050661 8.62 CAT MTHFR

Sources for Diabetic Angiopathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....